Clinical trials: Bulky Tumors
Cervical Cancer, Squamous Cell Carcinoma of Cervix
Intra-lesional Tumor Boost for Bulky Cervical Cancer
The goal of this clinical trial is to learn if adding a radiation boost (intra-lesional boost) works to treat patients with large-sized cervical cancer. It will also learn about the safety of this treatment.
- Trial name
- INTLECTUAL (NCT07435376)
- Testing
- intra-lesional boost IMRT, High Dose Rate Brachytherapy
- Where
- South Korea
- Volunteers
- 17 people
- Sponsor
- Seoul National University Bundang Hospital
Bulky Stage IIIC and IV Epithelial Ovarian Cancer, Fallopian Tube Cancer
First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer
The purpose of this study is to evaluate the role of an additional intraperitoneal chemotherapy with cisplatin and etoposide in bulky advanced epithelial ovarian cancer.
- Conditions
- Bulky Stage IIIC and IV Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- AICE (NCT01669226)
- Testing
- PEip (weekly) and TCiv, TCiv
- Where
- 7 sites in China
- Volunteers
- 215 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Lymphoma, Non-Hodgkin
Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy
The purpose of the study is to assess the response rate of patients with relapsed or refractory low-grade or transformed low-grade, CD20-positive, B-cell non-Hodgkin's lymphoma to Iodine-131 (I-131) tositumomab (Bexxar) therapy…
- Trial name
- NCT00490490
- Testing
- Bexxar (tositumomab), External beam radiotherapy (XRT), Potassium Iodide (KI)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Stanford University
Cervical Cancer
Dose-finding Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and Bulky IIA Cervical Cancer
This phase I study is designed to establish an optimal dose of paclitaxel, under a fixed cisplatin dose at 40 mg/m2, delivered every week for three weeks, as neoadjuvant therapy before radical hysterectomy in bulky (FIGO IB2 or…
- Trial name
- Chemothreapy (NCT00823186)
- Testing
- Phyxol(Paclitaxel)
- Where
- 3 sites in Taiwan
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Hodgkin's Lymphoma
Dual Point PET Scan in Early Stage Hodgkin Lymphoma Patients With Bulky Lesions
To assess specificity and overall accuracy of interim dual-point acquisition PET in predicting treatment outcome. The study is aimed at assessing the specificity of interim dual-point PET performed after 2 ABVD cycles to predict…
- Trial name
- 2P-HD-10 (NCT01399931)
- Where
- 6 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Ospedale Santa Croce-Carle Cuneo
Unresectable Malignant Neoplasm, Bulky Tumor
Proton and Proton-Photon Hybrid Partial Stereotactic Ablative Boost Radiotherapy (P-SABR) for Unresectable Large Tumors
This prospective, multicenter, observational cohort study will enroll 60 adults with unresectable larege tumors (longest diameter > 5 cm) who receive one of two treatment modes: (A) proton P-SABR, in which both the proton…
- Conditions
- Unresectable Malignant Neoplasm, Bulky Tumor, Solid Tumor
- Trial name
- LARGE-Proton (NCT07818798)
- Testing
- Proton P-SABR, Proton-Photon Hybrid P-SABR
- Volunteers
- 60 people
- Sponsor
- Peking University First Hospital
Cervical Cancer
Therapeutic Effect of Surgical Debulking of Metastatic Lymph Nodes in Cervical Cancer Stage IIICr
This study is a prospective, multicenter and randomized clinical trial (DEBULK trial) to determine the therapeutic effect of surgical debulking of bulky or multiple lymph nodes before concurrent chemoradiation therapy (CCRT) in…
- Trial name
- NCT05421650
- Testing
- CCRT, Surgical debulking of lymph nodes + CCRT
- Where
- 26 sites in India, Italy and 3 more
- Volunteers
- 240 people
- Sponsor
- CHA University
Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
Ribociclib (LEE011) Rollover Study for Continued Access
This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-sponsored ribociclib (LEE011)…
- Trial name
- NCT02934568
- Testing
- LEE011
- Where
- 13 sites in United States, France and 4 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Diffuse Large B-Cell Lymphoma
Hyperfractionated Dual Equivalent Fractionated Radiation Therapy
This study evaluates the feasibility and safety of bridging radiation therapy, including a novel method for comparing the effectiveness of hypofractionated versus hyperfractionated radiation therapy in participants with…
- Trial name
- HyDEF (NCT06898905)
- Testing
- Bridging Radiation Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Yale University
Local Advanced Non-small Cell Lung Cancer
Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC
This study is a Phase II study to evaluate the clinical efficacy and safety of Toripalimab combined with chemoradiotherapy for large-volume local advanced non-small cell lung cancer
- Trial name
- InTRist (NCT05888402)
- Testing
- Toripalimab, Concurrent chemoradiation therapy and consolidation immunotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hyperuricemia
Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma
The primary objective was to evaluate the efficacy of rasburicase in terms of prevention and treatment of hyperuricemia related to Tumor Lysis Syndrome (TLS) in 2 populations of adult patients, previously treated or not with…
- Trial name
- GRAAL2 (NCT00664144)
- Testing
- Rasburicase (SR29142)
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 33 people
- Sponsor
- Sanofi
Lymphoma
S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00070018
- Testing
- rituximab, Cyclophosphamide, doxorubicin hydrochloride
- Where
- 48 sites in United States
- Volunteers
- 46 people
- Sponsor
- SWOG Cancer Research Network
Cancer, Metastatic Cancer
Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors
The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.
- Conditions
- Cancer, Metastatic Cancer, Locally Advanced, Locally Advanced Solid Tumor
- Trial name
- NCT06416007
- Testing
- Lattice therapy (LRT)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Cincinnati
Lymphoma
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
This phase II trial studies how well chemotherapy based on positron emission tomography (PET) scan works in treating patients with stage I or stage II Hodgkin lymphoma.
- Trial name
- NCT01132807
- Testing
- Bleomycin Sulfate, Doxorubicin Hydrochloride, Procarbazine Hydrochloride
- Where
- 95 sites in United States
- Volunteers
- 164 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
This is a phase 2, single-arm, open-label study to evaluate the safety and efficacy of comprehensive bridging radiation therapy prior to CD19 CAR T-cell therapy for large B-cell lymphoma patients with bulky disease, defined as…
- Trial name
- NCT06104592
- Testing
- Comprehensive Ablative Bridging Irradiation (CABI), Chimeric Antigen Receptor T-Cell Therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Diffuse Large B-cell Lymphoma (DLBCL)
Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)
The purpose of this study is to evaluate the complete response (CR) rate after Intensified 1st cycle Rituximab plus 3rd cycles of R-CHOP in DLBCL
- Trial name
- NCT01054781
- Testing
- Rituximab
- Where
- South Korea
- Volunteers
- 91 people
- Sponsor
- Samsung Medical Center
Diffuse Large B-cell Lymphoma
Reduced Chemotherapy in Low Risk DLBCL
This is a clinical trial to compare the efficacy and safety of four cycles of R-CHOP followed by four cycles of Rituximab with six cycles of R-CHOP followed by two cycles of Rituximab in the treatment of de novo, low-risk…
- Trial name
- NCT02752815
- Testing
- Rituximab, Cyclophosphamide, Epirubicin
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Ruijin Hospital
Immunotherapy, Gastrict Cancer
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
To evaluate the clinical efficacy and safety of Tislelizumab combined with apatinib mesylate, oxaliplatin plus S1.
- Trial name
- NCT05223088
- Testing
- Tislelizumab, Apatinib Mesylate, oxaliplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fujian Cancer Hospital
Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Adding Spatially Fractionated Radiation Therapy to Standard Palliative Radiation for Improving Disease-Related Symptoms in Patients With Unresectable Solid Tumors
This clinical trial evaluates whether adding spatially fractionated radiation therapy (SFRT) to standard palliative external beam radiation therapy (EBRT) improves disease-related symptoms in patients with solid tumors that…
- Conditions
- Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm, Unresectable Solid Tumor, Malignant Tumor
- Trial name
- NCT07856394
- Testing
- Electronic Health Record Review, External Beam Radiation Therapy, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
NSCLC (Advanced Non-small Cell Lung Cancer)
Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer
This is a randomized, controlled, multicenter clinical study that enrolled patients with unresectable bulky stage III NSCLC, with PFS as the primary endpoint.
- Trial name
- NCT07560358
- Testing
- After chemoimmunotherapy induction, followed by concurrent/sequential chemoradiotherapy and subsequent immune consolidation and maintenance therapy., adebrelimab,Radiation Therapy,Radiotherapy
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences